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Objective: International guidelines for pre-participation screening of masters/leisure 
athletes to identify those that require medical assessment exist, but have not been 
implemented in mass-community based sports events. We determined the prevalence of 
runners who, according to these guidelines, would require a medical assessment before 
participating in a distance running event. 
Methods: Participants of the 2012 Two Oceans races (21.1 and 56 km) in South Africa (n = 
15,778) completed an online pre-race medical screening questionnaire using European pre-
participation screening guidelines. We determined the prevalence of runners that would 
require a pre-race medical assessment, based on risk factors, symptoms, and disease. 
Results: The pre-participation “self assessment of risk” screening identified 4,941 runners 
(31.3%; 95% CI 30.6–32.0) that would need to undergo a full pre-participation medical 
assessment prior to running, if the current pre-participation screening guidelines are 
applied. Although musculoskeletal complaints and prescription medication use were the 
main triggers for a medical assessment, 16.8% (n = 2657) runners should undergo medical 
evaluation for suspected cardiac disease based on the questionnaire results: 3.4% (n = 538) 
reporting existing CVD (very high risk) and 13.4% (n = 2119) reporting multiple CVD risk 
factors (high risk). Other possible risk factors were reported as follows: history of chronic 
diseases (respiratory = 13.1%, gastro-intestinal = 4.3%, nervous system = 3.8%, 
metabolic/endocrine = 3.5%, allergies = 13.9%); chronic prescription medication = 14.8%, 
used medication before or during races = 15.6%; past history of collapse during a race = 
1.4%. 
Conclusions: Current guidelines identified that > 30% runners would require a full medical 
assessment before race participation – mainly linked to runners reporting musculoskeletal 
conditions. We suggest a revision of guidelines and propose that pre-race screening should 
be considered to identify runners with a “very high,” “high,” and “intermediate risk” for 
medical complications during exercise. Pre-race screening and educational intervention 






Regular participation in  physical activity (> 150min  per week at moderate- to high-
intensity) has numerous health benefits, including the prevention and management of 
chronic non-communicable disease [1,2]. Recreational running has become an increasingly 
popular form of regular physical activity and participation in community based recreational 
distance running events such as the 21.1 km (half-marathon), marathon (42.2 km), and 
ultra-marathon races has concomitantly increased [3]. Annual reports from Running USA 
(http://www.runningusa.org/annual-reports – accessed on 1 March 2017) show an increase 
of > 12-fold in overall participation in marathon runners since 1976, specifically increases 
in participation in the older age groups (> 40 years). 
 
While the health benefits of exercise are numerous, medical complications during 
moderate- to high-intensity vigorous physical activity, such as distance running, in a 
variety of organ systems have been described [4–6] Acute cardiac events, including 
myocardial infarction and sudden  death, are described in both younger and older 
runners [7–10]. Determining the risk of sudden death during exercise, in particular 
during distance running events such as the half-marathon (21.1 km) and marathon 
(42.2 km) [11,12] using pre-screening tests and detailed diagnostics (ECG) has been 
proposed [5–8,13–16]. 
 
Pre-participation screening for CVD is routinely recommended and performed for younger 
competitive elite athletes across the world [17–22] but not in leisure athletes older than 35 
years, despite an exponentially higher risk of acute cardiac episodes in these older athletes 
due to increased incidences of atherosclerotic  coronary  artery  disease  [23].  Pre-
participation screening guidelines for masters (≥ 50 years) and leisure athletes have been 
proposed by the American Heart Association (AHA) [24], American College of Sports 
Medicine (ACSM) [25], Canadian  Physical  Activity  Readiness  Questionnaire  (PAR-Q+), 
and   the   Physical   Activity   Readiness   Medical   Examination (ePARMed-X+)  [26],  and  
the  European  Society  of  Cardiology (ESC)     together      with      the      European      
Association     of Cardiovascular Prevention and Rehabilitation (EACPR) [27,28]. 
 
These guidelines “provide a pragmatic and practical approach to identifying higher-risk 
individuals to minimize the risk of sudden cardiac death (SCD)” [28]. The screening process 
begins with a “self-assessment of risk” which is followed up by medical intervention for 
identified high-risk athletes. The “self-assessment of risk,” recommended by the ESC and 
EACPR, can be conducted by the individual athlete or by non-physician  health  professionals  
[28] and is based on the recommended AHA/American College of Sports Medicine (ACSM) 
pre-participation screening questionnaire for individuals at Health/Fitness facilities [29]. The 
initial “self-assessment of risk.” In Section 1, health information related to known 
cardiovascular disease, cardiovascular symptoms, medication use, and other health issues is 
collected and in Section 2, known risk factors for cardiovascular disease are identified. If the 
respondents provide one positive response to any question related to Section 1 (health 
information), or if 2 or more risk factors are identified in Section 2, they are advised to undergo 




high-intensity exercise, such as distance running [28]. More recently, a task force from the 
ACSM published revised screening guidelines, and in these new guidelines, risk factors for 
CVD (Section 2) were omitted [25]. 
 
We are only aware of one study where the ESC/EACPR screening guidelines were applied to 
adult participants > 40 years of age [30]. In this study, based on “self assessment of risk,” 
approximately 95% of women and 93.5% of men were advised to consult a physician 
before embarking on exercise [30]. We are not aware of any studies describing the outcome 
of the ESC/EACPR screening guidelines when applied to participants in mass community-
based endurance events. 
 
In the first of our SAFER (Strategies to reduce Adverse medical events For the ExerciseR) 
studies [5,31–33] we report a high risk of serious of cardiac and non-cardiac medical 
complications at endurance events [5]. 
 
In this study, as part of the ongoing SAFER initiative, we wanted to determine the 
prevalence of runners who, according to the current European guidelines for “risk self 
assessment,” would be at higher risk of acute cardiac medical complications and be 
required to undergo a medical assessment before participating in the Two Oceans 21.1 km 
or 56 km races. Furthermore, we wanted to determine the factors in the current guidelines 
that trigger this recommendation. As a secondary aim, we also explore the prevalence of 
other potential “risk factors” associated with serious non-cardiac medical complications 
such as other chronic systemic diseases, use of medication, and previous collapse during 





The Old Mutual Two Oceans Marathon races are mass community-based running events 
that take place annually during late summer in Cape Town, South Africa.  Approximately 
25,000  runners  are  attracted  to  the  two  main  events,  the 21.1 km (half-marathon)  and  
the  56  km  (ultra-marathon) races every year. Males  and  females  of  all  ages  older  than 
16 years can enter, and entries to the 21.1 km race are open to novice runners and 
require no qualifying time. Entries for the 56 km race requires completion of any one of 
the following qualifying times: a standard 42.2 km marathon in < 5 h, 50 km in < 6.5 h, 
56 km in < 7 h, 90 km in < 12 h, or a 100 km race in < 13.5 h. A high rate of acute 
medical complications, including sudden death, in the runners competing in the Old 
Mutual Two Oceans Marathon races [5,32] precipitated the design and implementation of 
an online pre-race medical screening program for all race entrants in 2012. 
 
Participants 
In 2012, all race entrants (n = 25,455) completed a pre-race medical screening 
questionnaire as part of the online registration process. Of these, 15,778 (62.0% of all race 




research purposes and these runners were designated as participants in this study. The 
study participants were representative (for gender, age, and race type) of all race entrants 
(Table 1). 
 
The 15,778 study participants consisted of 8,916 (56.5%) male and 6,862 (43.5%) female 
entrants. In the study group, compared to all entrants, there were equal proportions of 
athletes in the 21.1 km and 56 km races and in males vs. females. In the age  categories  
there  were  equal  proportions of runners in the age group 31 to 39 years old (All = 
31.7%, Study group = 28.5%), but there was a large proportion of runners in the younger 
(< 30 years) (All = 29.4%,  Study group  =  31.4%)  and  older  (>  40  years)  (All  =  
38.9%,  Study group = 40.1%) age groups (Table 1). 
 
 
For purposes of conducting research on this population, permission to investigate the 
prevalence of risk factors for cardiovascular disease, existing medical diseases, allergies, 
medication use,  and  injury history  during  endurance  running in the Two Oceans races 
was obtained from the Research Ethics Committee of the University of Cape Town (REC 
009/ 2011) (REC 030/2013) and the Research Ethics Committee of the University of 
Pretoria (REC 433/2015). 
 
Online pre-race medical screening questionnaire 
An online pre-race medical screening questionnaire (OPRMSQ) or “self-assessment of 




medical complications during moderate-to high intensity exercise such as a distance 
running race [6]. The questions  were  based  on  the ESC and the EACPR guidelines for 
pre-exercise screening [28] with additional questions on general prescription medication 
use, including medication use during racing and a past history of collapse during racing. 
 
The main elements of the questionnaire (Table 2) consisted of 2 injury-related questions 
(muscle cramping and running injuries) and 13 questions that included the following 
categories of medical history: cardiovascular disease (CVD), symptoms of CVD, risk 
factors for CVD, other chronic disease (respiratory disease, metabolic or hormonal 
disease, gastrointestinal disease, nervous system disease, renal or bladder disease, 
hematological or immune system disease, cancer, allergies). With the exception of a 
question regarding pregnancy, the OPRMSQ included all the questions in the AHA/ ACSM 
pre-participation screening questionnaire for individuals at Health/Fitness  facilities [29], 
as recommended by the  ESC and the EACPR for the pre-participation screening of leisure 
athletes engaging in moderate- to high-intensity exercise [27]. 
 
Statistical analysis 
All data from the runner and medical questionnaire database were analyzed using the 
SAS Enterprise Guide (V6.1) statistical package (SAS Institute Inc., Cary, North Carolina, 




Prevalence of risk factors for cardiovascular disease (CVD), symptoms 
of CVD, and existing CVD in runners 
The prevalence of existing CVD, symptoms of CVD, and risk factors for cardiovascular 
disease (CVD) in runners is depicted in Table 3. In this group of distance runners (n = 
15,778), 360 (2.3%; 95% CI 2.1–2.5) reported suffering from  existing CVD. The most 
common reported cardiovascular condition in  runners with existing CVD (n = 360) was a 
heart murmur (0.6%; 95% CI 0.5–0.7), followed by known coronary artery disease (0.5%; 
95% CI 0.4–0.6), and arrhythmia (0.4%; 95% CI 0.3–0.6) (Table 2). Other reported 
specific CVDs were a history of rheumatic   fever   (0.2%;   95%   CI   0.1–0.3),   and   
myocardial infarction (0.2%; 95% CI 0.1–0.3). In this category of “other,” less than 0.4% 
of runners reported existing CVD. 
 
Of the runners surveyed, 284 (1.8%; 95% CI  1.6–2.0) reported at least one symptom of 
CVD. The more common specific symptoms of CVD in runners were painful calves during 
walking (0.5%; 95% CI 0.4–0.6), a history of dizziness or fainting during exercise (0.4%; 
95% CI 0.3–0.5), pain in  the neck, jaw or arms (0.3%; 95% CI 0.2–0.4), swollen ankles 
(0.3%; 95% CI 0.2–0.3), shortness of breath with mild exercise (0.3%; 95% CI 0.2–0.3), 
and chest pain (0.20%; 95% CI 0.1–0.2) (Table 2). Other possible symptoms of CVD 
(water retention, palpitations, chronic cough) were reported by ≤ 0.2% of runners. The 
total number of runners who reported either known CVD or symptoms suggestive of CVD 














In  this  group  of  runners,  2,544  (16.1%;  95%  CI  15.5–16.7) reported at least one risk factor 
for CVD. The most common risk factor for CVD in runners was a combination of male and 
age > 45 years (15.7%; 95% CI 15.1–16.3). Other common specific risk factors for CVD 
included high blood cholesterol concentration (5.8%; 95% CI 5.5–6.2), high blood pressure 
(4.4%; 95% CI 4.1–4.7), and a family history of heart disease (4.4%; 95% CI 4.0–4.7). Less 
than 4% of runners reporting other CVD risk factors such as smoking, being overweight, or 
suffering from diabetes mellitus (Table 2). The total number of runners who reported more 
than one risk factor for CVD was 2,119, which is 13.4% of all the runners. 
 
Prevalence of chronic diseases in other organ systems in runners 
In this study, 2061 runners (13.1%; 95% CI 12.5–13.6) reported a  history  of  respiratory  
disease.  The  more  common  specific respiratory  diseases  were  reported  as  follows:  
allergies/hay fever (8.6%; 95% CI 8.2–9.1) and asthma (5.9%; 95% CI 5.5– 6.3) (Table 
4). Runners also reported a history of other chronic disease, including GIT disease (4.3%; 
95% CI 4.0–4.7, n = 683), metabolic   and   endocrine   disease   (3.5%;   95%   CI   3.2–3.8, 
n = 552), and kidney or bladder disease (2.3%; 95% CI 2.0– 2.5, n = 358). 
Furthermore, 13.9% (95% CI 13.3–14.4, n = 2189) runners reported a history of any 
allergy, while 14.8% (95% CI 14.2–15.3, n = 2333) runners reported the use of chronic 
prescription  medication. 
 
Prevalence of medication use by runners one week before, or during 
racing 
In this group of runners, 2,459 runners (15.6%; 95% CI 15.0– 16.2) reported using 
medication to treat injuries either before or during races. In the week before a race, 
runners commonly used anti-inflammatory medication (12.8%; 95% CI 12.3–13.3), 
specifically non-steroidal anti-inflammatory medications (NSAIDs) (9.1%; 95% CI 8.7–9.6), 
while 3.9% (95% CI 3.6–4.2) of runners reported using paracetamol, and 1.6% (95% CI 
1.4– 1.8) used cortisone in the week prior to a race (Table 5). 
 
During the race, the most common reported specific medication used was also anti-
inflammatory medication (7.8%, 95% CI 7.4–8.2), more specifically, the NSAIDs (4.9%; 
95% CI 4.6–5.3). In addition, 3.1% (95% CI 2.8–3.3) of the runners used paracetamol 
during a race, followed by the use of other analgesics (1.8%; 95% CI 1.6–2.0) (Table 5). 
 
Prevalence of past history of collapse during training or racing in 
runners 
In this group of runners, 196 (89.1%, 95% CI: 84.9 – 93.2) reported a history of collapse 
either during training or during a race. 
 
The total number of runners who reported any known underlying chronic diseases, 
and/or medication use, and/or a past  history  of  collapse  was  7,738,  which  is  49.1%  



















In  how  many  runners  did  the  pre-participation  “self assessment of 
risk” medical screening (using the ESC/ EACPR guidelines) identify 
the need to undergo a full pre-participation medical assessment prior 
to running? 
The pre-participation “self assessment of risk” screening identified 4,941 runners (31.3%;  
95%  CI  30.6–32.0)  that would need to undergo a full pre-participation medical 
assessment prior to running, if the current ESC/EACPR pre-participation screening 
guidelines are applied [27,28]. Of these runners, 16.8% (n = 2,657) runners should 
undergo medical evaluation for suspected cardiac disease based on the questionnaire 
results: 3.4% (n = 538) reporting existing CVD (very high risk) and 13.4% (n = 2,119) 
reporting multiple CVD risk factors (high risk). The specific criteria (by Sections 1 and 2 of 
the  AHA/ ACSM screening recommendations in the ESC/EACPR guidelines), that were 
responsible for the recommendation to undergo a  full  medical  assessment (expressed  as a  
% of the 4,941 runners that were identified), are depicted in Table 6. 
 
The main criterion that would lead to the recommendation for referral to undergo a full 
medical assessment before competing was a self reported musculoskeletal condition 
(54.9% of the runners that were identified). The use of prescription medication and the 
gender/age  criterion  (male  gender:  over 45 years) followed as criteria for referral. Risk 
factors associated with CVD, including a high serum cholesterol concentration, high blood 
pressure, and diabetes mellitus were also common criteria for referral. 
 
Of the 4,941 runners that were identified through the screening process, 22% were 
identified because of CVD risk factors,   23%   were   identified   because   of   other   
medical conditions  plus  one  other  risk  factor  for  CVD,  and  another 55% were 
identified because of other medical conditions, with no CVD risk factors. Almost half of 
the athletes with any one CVD risk factor were not identified for screening (1,996/ 
4,244). 
 
We also noted that 2% more 56 km runners (n = 1,630, 32.7%) were identified to undergo 
screening by the guidelines, compared to 21 km runners (n = 3,311, 30.7%), and 1.4% more 




The main finding of this study was that an online pre-participation “self-assessment of 
risk,” as currently recommended   by   European   guidelines   could   be   implemented 
successfully   during   pre-race   registration   in   a   community-based mass  sports   
participation  (distance  running)  event. In > 15,000 recreational distance runners, the 
pre-race screening tool identified that over 30% of entrants for this event would, according 
to current European  guidelines, require referral for a full medical assessment prior to 
participation in the  distance races (moderate-to-high  intensity exercise).  Additional  




(a) 2.3% runners reported suffering from existing CVD, 1.8% reported current symptoms 
suggestive of existing CVD, and 16.1% reported at least one risk factor for CVD; (b) the 
prevalence of other existing chronic diseases, by organ  systems was as follows: respiratory 
(13.1%), gastro-intestinal (4.3%), nervous system (3.8%), metabolic or  endocrine  system 
(3.5%); (c) 13.9% runners reported suffering from allergic disease; (d) 14.8% runners 
reported using chronic medication; (e) 15.6% of runners reported using medication to 
treat injuries 7 days before or during races; and (f) 1.4% of all runners reported a past 
history of  collapse  during  a race. 
 
International pre-exercise screening recommendations in leisure athletes [25,27,28] are 
currently not applied at community-based mass participation events and there are few data 
that these guidelines are indeed appropriate for pre-event medical screening of leisure athletes. 
To our knowledge, this is the first study to report pre-participation screening data to determine 
the risk profile of participants in such a community-based mass participation distance 
running event and we cannot compare our main finding to any other similar population of 
recreational athletes. We do note that distance running events (21.1 km and ultra-marathon), 
such as the ones described in our study, are hosted all over the world, are becoming 
increasingly popular, and that participation in these events is encouraged as part of promoting 
a healthy active lifestyle. As far as we are aware, in most cases, these events are also open- 
entry and attract runners from all age groups. This can result in an increased proportion of 
runners that require no pre-entry qualifying times and enter races where there are no pre-
event medical screening criteria. 
 
Data reported on medical complications of participants during such events are largely limited 
to retrospective analysis of the incidence of sudden cardiac arrest and death. However, 
cardiac arrest and sudden death only represent the most severe medical complications during 
such events. There are few published data regarding other medical complications that do not 
necessarily lead to cardiac arrest, but are still regarded as potentially serious and even life-
threatening medical complications and all medical complications during these events [5,34]. 
 
We show that the presence of musculoskeletal complaints (54.9% of runners) was the main 
criteria identified by the current European guidelines [27,28], for recommending consulting a 
physician before exercise, and that 32.34% of the runners that would be referred for a 
medical assessment, reported musculoskeletal complaints as their only criteria for referral. 
Distance running is associated with a high prevalence of musculoskeletal complaints; 
therefore, we question the value of including the history of a musculoskeletal problem as part 
of a screening tool for this population as this would require referral of a large number of runners 
for pre-participation medical examinations. 
 
The  use  of  prescription  medication  (47.2%  of  runners) was the next most common 
criteria identified by the current European guidelines [27,28], for recommending 
consulting a physician before exercise. The potential risk of a medical complication 
during exercise, as a result of prescription medication, can vary greatly and is related to 




effect profile of the medication. Some pharmacological agents may be associated with an 
increased risk of developing cardiac arrhythmias [35–38], renal complications including 
acute renal failure [39], rhabdomyolysis [40,41], gastrointestinal bleeding [42–44], and 
risk of tendon injuries including acute tendon rupture [45,46]. We recommend that a 
screening tool could be modified to include more specific information about classes of 
medication that may be associated with increased risk of medical complications during 
exercise. 
 
In our study, we did explore the prevalence of underlying chronic medical conditions in 
this population of runners. We identified that 2.3% of all runners reported known existing 
cardiovascular disease (CVD) and the most common CVD’s were coronary artery disease 
(0.5%), and arrhythmia (0.4%). A history of a heart murmur was reported by 0.6% 
runners, but this may not necessarily indicate CVD. Furthermore, 1.8% runners reported 
symptoms that may be suggestive of CVD, but we acknowledge that some of the 
symptoms, such as painful calves when walking and chronic cough, are not specific and 
may not indicate underlying CVD. 
 
As is recommended by international guidelines [25,28], we would strongly recommend 
that runners with existing  CVD and those with symptoms suggestive of CVD undergo a full 
medical assessment before participating in moderate- to high-intensity exercise such as 
distance running events, because they represent a “very high risk” group for developing 
potentially serious acute cardiovascular complications during a distance-running  event. 
 
Our data showed that 16.1% of runners reported at least risk factor for CVD, with 
13.4% reporting more than one risk factor. The most common specific risk factors for 
CVD were high blood cholesterol concentration (5.8%), high blood pressure (4.4%), and 
a family history of heart disease (4.4%). In addition, over 15% of the runners were 
males > 45 years. According to the European guidelines [27,28], older runners (males 
≥ 45 years; females ≥ 55 years) with one or more risk factors for CVD, and runners of 
younger age with two or more risk factors for CVD require medical assessment before 
engaging in moderate- to high-intensity exercise such as distance running. The recently 
revised recommendations by the ACSM excluded risk factors for CVD as criteria for a 
pre-exercise medical assessment [25]. However, in our experience at the Two Oceans 
races, runners who died or suffered from serious life threatening medical complications 
were mostly  in this ‘high risk’ group. Therefore, we would recommend that runners 
with ≥ 1 risk factor for CVD undergo a full medical assessment before participating in 
these moderate- to high- intensity exercise events, until there is stronger evidence that 
the risk of an acute medical complication in runners falling into this category is not 
increased. 
 
In  our  population  of  runners,  the  prevalence  of  existing disease in other organ 
systems varied between 1.9% (cancer) to 13.1% (respiratory disease). We recognize that 
there is a variable risk of a medical complication in this group of runners and the risk is 




or absence of multi-organ complications of a disease, (b) the level of control of the disease, 
(c) side effects of any treatment (e.g. medication, radiation therapy, previous surgery), 
and (d) the effect of significant environmental conditions or  physiological  stress such as 
moderate-to-high intensity exercise in “unmasking” disease exacerbation or any of the 
above (a to c). We recognize the complexity and individual variability  of  determining the 
specific risk of a medical complication during  exercise in the presence of an underlying 
chronic disease.  We  suggest that underlying chronic disease constitutes at least an 
“intermediate risk” for medical complications during exercise and should be included in 
any pre-race screening program for leisure athletes, and that these runners undergo a full 
medical assessment before participating in these events. 
 
The finding that 15.6% of runners reported ingestion of pharmacological agents, mainly 
anti-inflammatory medication (7.8%), and more specifically NSAIDs (4.9%), in the 7 days 
before or during races is of concern. The association between NSAID use and medical 
complications is  known,  specifically the risk of acute renal [39] and gastro-intestinal 
complications [42–44]. We therefore suggest that the use of these medications during 
racing also constitutes an “intermediate risk” for medical complications during exercise 
and should be included in any pre-race screening program for recreational athletes. 
 
Finally, in our study, 1.4% runners reported a past history of collapse during exercise. It is 
well-established that a history of collapse during exercise can be indicative of a more serious 
medical complication  [47–49], therefore we suggest that this constitutes an “intermediate 
risk” and this information should be included in any pre-race screening program for 
recreational athletes. 
 
The main strengths of this study are that it is, as far as we are aware, the first study to 
report on the feasibility and outcomes of an online pre-race medical screening tool for a 
large population of recreational runners participating in a mass community based 
distance running event. Furthermore, we report the data on a large sample size that is a 
representative sample (age,  gender, and  race  type) of  race  entrants with  a response rate 
of 62.8%. 
 
Limitations of this study are firstly that we note that older males were under-represented 
in the consent sample and this is a limitation since the proportion of athletes identified for 
screening could then be under-reported in this study. A further limitation is that data are 
self-reported and that not all runners may have fully understood the questions asked or 
may have under-appreciated the importance of the request for accuracy in the answers. 
Therefore, again the data presented in this article may indeed be under-reported. If this is in 
fact the case, the  risk profile of runners in this the sample may under-represent the actual 
risk profile. Finally, although runners in the higher risk categories (existing CVD and those 
with risk factors  for  CVD) were advised (by email communication) to undergo medical 
evaluation, we do not report data on how many actually took up this advice and how many 





Opinion and recommendations 
We describe the development and implementation of a relatively low-cost pre-race screening 
tool to determine the “self-assessment of risk” of a medical complication during exercise in 
a community-based mass participation distance running event. We show that by using 
current screening guidelines, > 30% of all runners entering for these events would require a 
full medical assessment, where a history of a musculoskeletal complaint and the use of 
prescription medication were the main criteria in the existing guidelines that triggered a 
referral to undergo a full medical assessment. We suggest a revision of the screening 
guidelines triggering a full medical  assessment  and  propose risk stratification and 
educational intervention (Table 7) as follows: (1) excluding the question on musculoskeletal 
complaints from triggering a full medical assessment, (2) including a question on 
prescription medication but refining it for specific classes of drugs that could potentially 
increase the risk of medical complications during exercise, and (3) including questions on 
other chronic diseases with organ system and disease specific recommendations on full 
medical assessment. Finally, future studies, should determine  the  feasibility  and  
implementation of such a screening and educational intervention program on reducing 
medical complications  during  these events.  This pre-race screening program is ongoing 
and has already been implemented in other large endurance events. In future, we will 
continue to report on the relationship of the risk profile of endurance athletes (“very high 
risk,” “high risk,” and “intermediate risk” groups) and the actual risk of medical 
complications during endurance events. These data will assist in decision-making regarding 
pre-participation  screening  guidelines  for these leisure distance-running athletes. 
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